GLP-1 Microdosing and Longevity; Near 30% Weight Loss in Trial; 2025’s Top Research
(MedPage Today) — As part of a longevity push, telehealth company Noom is now offering microdoses of GLP-1 receptor agonists outside the labels’ indications, including for people with a normal body mass index and no diabetes. In a phase III trial…
Pharmaceuticals, Vol. 18, Pages 1896: Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process
Pharmaceuticals, Vol. 18, Pages 1896: Production of a Dulaglutide Analogue by Apoptosis-Resistant Chinese Hamster Ovary Cells in a 3-Week Fed-Batch Process Pharmaceuticals doi: 10.3390/ph18121896 Authors: Rolan R. Shaifutdinov Maria V. Sinegubova Ivan I. Vorobiev Polina E. Prokhorova Alexey B. Podkorytov Nadezhda A. Orlova Background: Dulaglutide, a GLP-1-IgG4 Fc fusion, is a long-acting GLP-1 receptor agonist […]
OrsoBio obesity data; Monte Rosa’s prostate cancer pill; Development pacts for Adaptive and SandboxAQ
Plus, news about: Hansoh, Caris-Genentech, Royalty, LIB, Greenwich LifeSciences, Gubra, J&J, Sprout, Tiziana and Vor. 💊 OrsoBio’s early obesity data: When combined with Lilly’s tirzepatide, OrsoBio’s oral obesity drug TLC-6740 led to an additional …
Popular weight-loss drugs may lower cancer risk, finds large study
Exciting new findings indicate that GLP-1 weight-loss medications might dramatically reduce the likelihood of 10 types of cancer linked to obesity for patients with type 2 diabetes, outperforming insulin. However, there’s no observed benefit for postmenopausal breast or thyroid cancers.
Form Health Simplifies GLP-1 Coverage Opportunities for Employers with Transparent, Predictable Pricing
BOSTON–(BUSINESS WIRE)–Today, Form Health, the national leader in science-based obesity and cardiometabolic care, announced access to new programs that provide employers with transparent, predictable access to obesity management medications from Eli Lilly and Company (Lilly) and Novo Nordisk (Novo), helping organizations offer comprehensive, wraparound care while controlling costs. This builds on Form’s work with both […]
GLP-1 adoption is rising steadily – and reshaping pack size, portfolio strategy and volume
From cereal and granola to snacks and soda, Big Chalk’s Fall 2025 report outlines where GLP-1 users are cutting back – and what brands should do next.
STAT+: Pharmalittle: We’re reading about obesity drug lawsuits, Ramaswamy’s latest startup, and much more
Rise and shine, another busy day is on the way. We can tell because the official mascots got an early start chasing down cats, squirrels, and other creatures darting about the Pharmalot campus. And then there is the noisy parade of vehicles passing nearby on their way to who knows what? As for us, we […]
Weight-Loss Drugs Like Wegovy Fail To Lower Obesity-Related Cancer Risks
Researchers analysed 48 previously-conducted trials which examined the safety and efficacy of GLP-1 drugs on people with type 2 diabetes, overweight, or obesity. These studies involved a total of more…
Injection‐site and dermatologic reactions associated with glucagon‐like peptide‐1 receptor agonists: Insights from meta‐analysis of randomised controlled trials and real‐world evidence
Abstract Aims Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes mellitus and obesity, with once-weekly dosing that supports adherence. However, injection-site reactions (ISRs) and dermatologic events have been recognised, ranging from mild local events to rare systemic hypersensitivity reactions that may cause discontinuation. To evaluate dermatologic and ISR safety of […]
President Lee urges gov’t to review national insurance coverage for hair loss, obesity treatments
A live broadcast of President Lee Jae Myung delivering a policy briefing to the Ministry of Health and Welfare airs on televisions in the main concourse of Seoul Station in Yongsan District, central Seoul, on Dec. 16. [NEWS1] President Lee Jae Myung on Tuesday called on the Health Ministry to review whether the national […]